HealthBusiness Insider Techabout 9 hours ago
Agios Presents RISE UP Phase 3 Results at EHA 2026
1 min read
Agios presented 52-week RISE UP Phase 3 results for mitapivat in sickle cell disease at the EHA 2026 plenary session. The trial met its primary hemoglobin response endpoint and key secondary endpoints on hemolysis markers. Mitapivat did not reach statistical significance for reducing sickle cell pain crises or improving fatigue overall.
Level
Hype check
Tap to vote and see what everyone thinks.
